NEWS | Launch of revised CTIS transparency rules

May 8, 2024
|

Starting June 18, 2024, the revised transparency rules Clinical Trials Information System (CTIS) will become applicable with the launch of a new version of the CTIS public portal.

The updated rules strike a balance between transparency of information and protection of Commercially Confidential Information (CCI). They benefit patients, because key clinical trial information, that patients flagged as being most relevant for them, is published early. They also introduce process simplifications that benefit clinical trial sponsors who have to protect commercially confidential information and personal data.

Key Change: Say goodbye to the deferral mechanism! Under the updated rules, sponsors are no longer permitted to delay the publication of certain data for up to 7 years post-trial. This significant change ensures that trial information is made available to the public in a timelier manner, enhancing transparency and accountability in clinical research.

What to Expect?

Increased transparency: With the removal of the deferral mechanism, more trials will be publicly available on the new CTIS portal. This means that stakeholders, including patients, researchers, and regulatory authorities, will have access to a broader range of trial data, fostering greater transparency and trust in the clinical research process.

Data disclosure timelines aligned with the updated rules: The revised transparency rules will establish clear timelines for the disclosure of trial information, ensuring consistency and adherence to regulatory requirements. This alignment will streamline the process for sponsors and improve accessibility to critical trial data for all stakeholders.

What You Can Do Now:

Explore the quick guide: Take advantage of the quick guide, which provides a comprehensive breakdown of the timelines for publishing trial information. This resource will help sponsors understand their obligations under the updated rules and plan accordingly.

Watch the CTIS Bitesize talks: Gain valuable insights into the rule changes by watching the CTIS Bitesize talks. These informative sessions will offer practical guidance and best practices for navigating the updated transparency requirements.

Mark your calendars: Don’t miss the follow-up talk scheduled for June 20, 2024. This session will provide further support and clarification on the revised rules, helping sponsors adapt their business processes effectively.

 

For further information, contact us at: [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

NEWS | FDA draft guidance on FAQs

The FDA issued a draft guidance on November 18 titled “Frequently Asked Questions: Developing Potential Cellular and Gene Therapy Products.” This guidance aims to assist

NEWS | Update from FDA

This guidance is intended for holders of Type II active pharmaceutical ingredient (API) drug master files (DMFs) that will be referenced in an abbreviated new drug application (ANDA), or a prior approval supplement (PAS) to an ANDA. This guidance explains how FDA incorporates a program enhancement agreed upon by the Agency and industry as part of the negotiations relating to reauthorization of the Generic Drug User Fee Amendments (GDUFA), as described in “GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023- 2027” (GDUFA III commitment letter). Specifically, this guidance describes instances when an early assessment or “DMF prior assessment,” could be requested by a DMF holder and the circumstances under which FDA would commence an early assessment of Type II API DMFs 6 months prior to an ANDA or PAS submission referencing the DMF. It also provides recommendations for such DMF holders when making a request. The guidance does not apply to Type II API DMFs used to support new drug applications (NDAs), submissions related to ANDAs that are not described above, or any other types of DMFs.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting